Fermenta Biotech Limited has submitted its quarterly compliance certificate to BSE Limited under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The filing, dated April 15, 2026, confirms the company's adherence to regulatory requirements for dematerialization processes.

Regulatory Compliance Certificate

The certificate confirms that during the quarter ended March 31, 2026, all securities received for dematerialization were processed in accordance with regulatory guidelines. The company has certified two key compliance aspects:

Registrar Confirmation

MUFG Intime India Pvt. Ltd., formerly known as Link Intime India Pvt. Ltd., serving as the company's Registrar and Transfer Agent, provided supporting confirmation dated April 6, 2026. The registrar confirmed that all securities received from depository participants during the quarter were properly processed within prescribed timelines.

Key highlights from the registrar's confirmation include:

• All dematerialization requests were confirmed or rejected to depositories as required
• Security certificates were mutilated and cancelled after due verification
• Depositories' names were substituted in the register of members within prescribed timelines
• No rematerialization requests were received during the quarter

Corporate Details

The certificate was signed by Company Secretary and Head – Legal Varadvinayak Khambete, confirming the company's commitment to maintaining regulatory compliance in its securities operations.

Fermenta Biotech Limited announced its unaudited financial results for the quarter and nine months ended December 31, 2025, showing mixed performance with quarterly revenue decline offset by strong nine-month growth. The Board of Directors approved these results at their meeting held on February 9, 2026, with regulatory compliance filing completed on February 10, 2026.

Quarterly Consolidated Performance

The third quarter showed challenging performance with consolidated revenue declining year-on-year but demonstrating sequential improvement from the previous quarter.

Nine-Month Consolidated Results

The company delivered impressive consolidated performance for the nine-month period, with significant growth across key metrics driven primarily by the Vitamin D3 human nutrition segment.

Standalone Financial Performance

The standalone operations also reflected similar trends with quarterly challenges but strong nine-month performance.

Business Segment Performance

The nutrition business demonstrated strong growth momentum, particularly in the Vitamin D3 segments, with human nutrition volumes growing 46% and animal nutrition volumes increasing 52% during the nine-month period.

Regulatory Compliance and Publication

Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company published its unaudited financial results in Business Standard (English) and Sakal (Marathi) newspapers dated February 10, 2026. The regulatory filing was completed by Company Secretary & Head - Legal Varadvinayak Khambete, confirming compliance with all disclosure requirements.